Dendritic cell (DC) vaccines are typically produced through the ex vivo generation of DCs harvested from patients and stimulated with either tumor antigens or mRNA-expressing MHC molecules, before being administered back to patients (118, 119). Here, HLA-C is linked to neoplasm.